Mettler-Toledo (MTD) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $26.82B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Patrick K. Kaltenbach |
| IPO Date | 1997-11-14 | CAGR | 5.59% |
| Employees | 18,100 | Website | www.mt.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.12% | Total Yield | 0.12% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $32.28B | P/E | 30.5 | Forward P/E | 25.88 | PEG | 4.65 |
| P/S | 160.04 | P/B | -15719.03 | P/CF | 730.38 | P/FCF | 825.88 |
| Sales | $4.09B | Sales 1Y | 6.78% | Sales 3Y | 3.52% | Sales 5Y | 26.21% |
| EPS | $43.51 | EPS 1Y | 6.48% | EPS 3Y | 8.46% | EPS 5Y | 56.73% |
| Sales QoQ | -16.16% | EPS QoQ | -40.44% | Sales QoQ Avg | 2.38% | EPS QoQ Avg | 6.25% |
| Gross Margin | 57.79% | Operating Margin | 28% | Profit Margin | 21.4% | ROCE | 44.72% |
| ROA | 24% | ROE | -610% | Altman Z Score | 10.14 | Piotroski Score | 7 |
| Current Ratio | 1.2 | Quick Ratio | 0.84 | Cash Ratio | 0.05 | Op. CF Ratio | 0.13 |
| Debt/Equity | -53.21 | Debt/Assets | 0.61 | Lt Debt/Equity | -51.61 | Lt Debt/Cap. | 1.02 |
| Intrst Cov. | 16.63 | Inventory Turnover | 4.26 | Asset Turnover | 1.11 | Receivables Turnover | 5.77 |
| Enterprise Value | $32.28B | P/E Ratio | 30.5 |
| Forward P/E | 25.88 | PEG Ratio | 4.65 |
| P/S Ratio | 160.04 | P/B Ratio | -15719.03 |
| P/CF Ratio | 730.38 | P/FCF Ratio | 825.88 |
| EPS | $43.51 | EPS Growth 1Y | 6.48% |
| EPS Growth 3Y | 8.46% | EPS Growth 5Y | 56.73% |
| Revenue Growth 1Y | 6.78% | Gross Margin | 0.58% |
| Operating Margin | 0.28% | Profit Margin | 0.21% |
| ROE | -6.1% | ROA | 0.24% |
| ROCE | 0.45% | Current Ratio | 1.2 |
| Quick Ratio | 0.84 | Cash Ratio | 0.05 |
| Debt/Equity | -53.21 | Interest Coverage | 16.63 |
| Altman Z Score | 10.14 | Piotroski Score | 7 |
Mettler-Toledo (MTD) valuation & financials
Mettler-Toledo (MTD) has a market capitalization of $26.82B and trades at a price-to-earnings ratio of 30.5. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Mettler-Toledo's revenue grew +6.8% over the last year.
Mettler-Toledo's next earnings report is scheduled for July 30, 2026 after market close; analysts estimate EPS of $10.78.
Mettler-Toledo (MTD) — frequently asked questions
When does Mettler-Toledo (MTD) report earnings next?
Mettler-Toledo is expected to report earnings on July 30, 2026 after market close. Analysts estimate EPS of $10.78.
What is Mettler-Toledo's market cap?
Mettler-Toledo (MTD) has a market capitalization of $26.82B.
What is MTD's P/E ratio?
Mettler-Toledo trades at a price-to-earnings ratio of 30.5, with trailing twelve-month EPS of $43.51.
How fast is Mettler-Toledo growing?
Mettler-Toledo's revenue grew +6.8% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)